Try our Advanced Search for more refined results
Life Sciences - January, 2021
348 articles
- Full Fed. Circ. Told State Universities Immune From IPR
- Drugmakers Must Face Fraud Claims In Valsartan MDL
- NJ Justices Won't Second-Guess Revival Of J&J Talc Cases
- Fowler White Avoids DQ, But Clients Sanctioned Over Emails
- AstraZeneca Hit With Investor Suit Over COVID-19 Vaccine
- Only Calif. Buyers Win Class Cert. In Joint Pill False Ad Suit
- 3 Firms Guide Biotech's $110M PIPE, Buy Of PE-Backed Co.
- Mass. Court Overturns Cost Ruling In Boston Drug Test Case
- Health Hires: Sidley Austin And King & Spalding
- EU Sets Temporary Export Controls On COVID-19 Vaccines
- Mass. High Court Tosses Suit Over Genzyme's Arthritis Device
- Partner Exits Firm Over Abuse Allegations Facing Colleague
- Nabriva Gets Initial Nod For $3M Investor Settlement
- UK Litigation Roundup: Here's What You Missed In London
- 4 Highlights As Biden Starts Scrubbing Trump's Health Legacy
- Feds Can't Dodge Gilead HIV Patent Counterclaims
- Mallinckrodt Seeks To Move Acthar Cases To Delaware
- Coronavirus Litigation: The Week In Review
- House Panel Probes $79M In Ventilator Deals For Abuse
- Novartis Must Face Ex-Lab Worker's Disability Bias Claims
- 9th Circ. Urged To Toss SmileDirect Harassment Suit
- ConEd Worker Fired For Medical Pot Use Can Sue, Court Says
- Real Estate Rumors: Vision Properties, Deutsche Bank, Stiles
- Watchdog 'Deeply Troubled' By Gaps In Feds' Vaccine Rollout
- Paul Weiss-Bound Orrick Attys Exit Theranos Case
- Deals Rumor Mill: Fenway Sports Group, KKR, 23andMe
- Feds Say Health Co. Used Masters, Derby Trips As Kickbacks
- Ex-Acclarent Execs Get $1.5M Fines Stayed Amid Appeal
- New Ariz. Law Practice Rules May Jump-Start National Reform
- US Merck Seeks To Upend Pfizer Pneumonia Vaccine Again
- Medical Device Co. Exec Gets 4 Months For Embezzling $1M
- 2 Firms Steer Materials Co.'s £403M Bet On UK Manufacturer
- Sanofi To Bottle Pfizer's Vaccine While It Works On Its Own
- Nevada Pot Testing Lab Doctored Results, Regulators Say
- Meet The Diverse Set Of Attorneys Leading The Elmiron MDL
- PTAB Weighs Novelty Of Bio-Rad DNA Microfluidics Techs
- Judge Polster Talks Senior Status And Opioid MDL's Future
- HHS Emergency Money Was Misappropriated, Watchdog Says
- States Urged Not To Use Opioid Mega-Deals For Budgets
- Real Estate Rumors: Kushner, Talis Biomedical, Ivy Realty
- Special Master Urges Toss Of Opt-Out Valeant Investor Suit
- 6 Firms Guide Advanz Pharma's $846M Nordic Capital Deal
- Pot Testing Co. Says Equipment Maker Sold Faulty Machines
- Nurse Says Fingers Can't Bend After Using Jewel Sanitizer
- NJ Court Lends Support To FDA Evidence In Mesh Cases
- Opioid MDL Judge Takes Senior Status, Setting Up Biden Pick
- ConMed Says Chubb Should Cover Chemical Exposure Claims
- Full Fed. Circ. Won't Take Up Hatch-Waxman Act Venue Limits
- Pot Sales Tracker Metrc Loses Mo. Fight To Collect Fees
- FDA Puts Mexican Sanitizers On Import Alert Over Toxin
- Eli Lilly Says HHS Drug Discount Rule Will Cost It Billions
- Judge Doubts Walmart's Preemptive Opioid Suit Can Prevail
- Fresenius Asks 3rd Circ. For Partial Redo Of Generics Opinion
- 10th Circ. Won't Revive J&J Unit Breast Implant Suit
- Alsup Slams UnitedHealthcare For 'Cherry-Picking' Facts
- Coronavirus Regulations: A State-By-State Week In Review
- Do Virus Response Liability Protections Cover Vaccinations?
- 10 Tips For Your Next Virtual Court Appearance
- 4 Firms Steer SPAC's $300M Israeli Medical Pot Co. Tie-Up
- PhRMA Latest To Sue HHS Over Pharmacy Discounts
- Ga. Board Can't Claim Immunity In SmileDirect Case, Feds Say
- J&J's Bid To Ax $15M Mesh Verdict Meets Skeptical NJ Court
- Feds Fire Back At Bid To Retry MiMedx Execs' Fraud Case
- Imerys Gets Nod On Updated Ch. 11 Plan Disclosures
- Companies Boost IPO Sizes As Another Blistering Week Starts
- Ex-Indivior Parent Withdraws $1.4B Claim Over Suboxone
- After Trump, Dem Probes May Turn To Companies
- Becton Investor Says Insiders Dumped Stock Ahead Of Recall
- 'Pharma Bro' Shkreli Can't Have FTC Prison Call Transcripts
- Eidos Therapeutics Investor Seeks Docs On BridgeBio Deal
- FTC Says Endo, Impax Cut 2nd Opana ER Pay-For-Delay Deal
- Drugmakers Must Face Warranty Claims In Valsartan MDL
- EpiPen Buyers Want Remote Testimony In Pricing MDL
- J&J, Bausch Beat Talc Products False Ad Claims
- Pa. County Says Medical Pot User Can't Guard Drug Offenders
- Merck Drops COVID-19 Vaccines After Disappointing Trials
- Don't Let Lies Infiltrate The Mediation Process
- Former Insys Execs Win 7th Virus-Induced Prison Delay
- High Court Won't Decide Arbitration Carveout Question
- Justices Reject Heart Monitor Patent Eligibility Case
- Judges On Race: Lack Of Data Deters Criminal Justice Reform
- Ret. Fed. Judges Call On Telecoms To Lower US-China IP Heat
- Raucous 2021 Awaits FCA Litigants After Low-Key Year
- Failure To Warn Claims Axed From Biomet Hip Implant Suit
- 1st Circ. Affirms Ex-Aveo CFO Committed Securities Fraud
- Polsinelli Says Clients' 'Slacking Off' Claims Are 'Meritless'
- US, Smith & Nephew Tell Justices PTAB Is Constitutional
- Diverse Atty Group Wins Lead Counsel In Elmiron MDL
- New Lead Plaintiff Seeks Cert. In Allergan Investor Action
- ITC To Probe Chinese Co. After Kan. AG Warns Of IP Theft
- Judge Won't DQ Class Rep In Suboxone 'Hopping' Suit
- BakerHostetler Picks Up IP Partner From Polsinelli
- NJ Employers Weigh Vaccine Rules Against Legal Liability
- DuPont, Others Commit $4B To 'Forever Chemical' Liabilities
- Cannabis Bill Roundup: A New Slate Of State Pot Reforms
- Insys Execs Safe In Prison With Biden Vaccine Plan, Feds Say
- 'Defective' Or 'Ordinary': PTAB Denials Suit Heats Up In Calif.
- 6th Circ. OKs Block On Chinese Heart-Device Sales In IP Fight
- Health Hires: Inspire Medical, Squire Patton Boggs
- Del. Books And Records Ruling Offers 4 Lessons For Cos.
- Taxation With Representation: Wilson, Faegre Drinker, Weil
- Breaking IP Barriers: Q&A With Finnegan's Mareesa Frederick
- Biotech Co. Vows Corporate Reforms To End Securities Suits
- Fed. Circ. Judge Calls High Court IP Decisions 'Inconsistent'
- Wash. Man Charged With Selling Untested COVID-19 Vaccine
- Bill To Recategorize Cannabis Kicks Off Federal Pot Reform
- Insys Founder To Pay NJ $5M In Opioid Bribery Settlement
- Brazil Conditionally Clears $825M Takeda Drug Divestment
- Ventilator Co. Says Rival's Poaching Hindered COVID-19 Work
- Prevail Investors Want Records From $1B Eli Lilly Deal
- Young Living's Oils Aren't Therapeutic, Buyers Claim
- Deals Rumor Mill: Joby Aero, Polynt-Reichhold, Starboard
- MLB Looks To Put Atty On Hook For Ex-Pitcher's Sanctions
- Faegre, Latham Drive $1.1B Boston Scientific-Preventice Deal
- Law Firms Should Note GCs' Growing Focus On Biz Strategies
- Biden To 'Fully Use' Defense Production Act In COVID-19 Plan
- Dentons Names Co-Head Of Its So. Cal. Venture Tech Group
- Biden DOJ May Ax Ban On 3rd-Party Donation Settlements
- Trump's Final Pardons Erase High-Profile Health Convictions
- Bard Mesh Expert's Bellwether Testimony 'Irrelevant': Patient
- Walmart Hit With Investor Suit Over DOJ Opioid Crisis Probe
- Real Estate Rumors: Yoya, Northeast Capital, Liberty Bank
- Latham-Led Medical Device Company Returns To IPO Market
- Takeda Pharmaceuticals Sued Over $1.8B Retirement Plan
- Mylan Wants Out Of Investor Suit Over FDA Inspections
- How Defense Production Act May Affect Vaccine Supply Chain
- Purdue Committees Get OK To Join Insurance Suits
- Queen's Gambit SPAC Among 6 That Raised $1.4B Via IPOs
- Illumina Rival Infringed DNA Sequencing IP, UK Court Rules
- 6 Changes The Legal Industry Should Prepare For
- DLA Piper, Cooley Craft Up To $510M Deal For Cardiva Medical
- Bayer Must Face Bulk Of Takeda's Hemophilia Drug IP Suit
- Pot Co. Says Oklahoma Residency Rule Unconstitutional
- PTAB Denies Bid To Review Eye Shot Patent, Citing ITC Case
- Lead Plaintiff In Endo Investors' Suit Slams Other Bids
- Hemp Biotech Biz Beats Investor Suit Over SEC Probe
- 4 Cos. Join IPO Pipeline Seeking To Raise $3.9B Total
- Drug Benefits Co. Valued At $1.1B In PE Deal Led By 3 Firms
- Genomic Testing Co. Preps $100M IPO Led By Cooley, Latham
- 11th Circ. Upholds $20M Punitive Award Against Philip Morris
- Purdue Insurer Says Committees Can't Bring Coverage Suits
- Arizona May Have Nudged US Law Firms Toward Future IPOs
- Coronavirus Regulations: A State-By-State Week In Review
- Mylan Can't Escape EpiPen Distributors' Antitrust Claims
- BPCIA Info Exchange Is Failing To Streamline Patent Litigation
- Biden Taps Trans Doctor For HHS Assistant Secretary
- 'Pharma Bro' Shkreli Again Denied Early Prison Release
- Shook Hardy Opens NYC Office With 2 Pharma Partners
- Iancu Resigns As USPTO Director, Urges Eligibility Reform
- Koch-Tied Org. Urges Miss. Justices To Keep Medical Pot Vote
- FCC Exempts Certain Pharma Calls From TCPA Rules
- Mallinckrodt OK'd To Pay Fees In Ch. 11 Despite Outcry
- Justices Reject Merck Bid To Revive $2.5B Patent Verdict
- Novo Joins Challenge To HHS Pharma Discount Opinion
- Miss. Businessman Gets 18 Years For $288M Tricare Fraud
- Fed. Circ. Sticks With Ruling In Bard's $68M Patent Fight
- Thermo Fisher Shells Out $876M For Viral Vector Maker
- Sanofi Prevails Over Mylan At Fed. Circ. On Jevtana Patent
- Ex-Insys Manager Frets Over 'Prison Parenting' In Delay Bid
- Real Estate Rumors: IQHQ, Beyond Meat, C-III Capital
- Imerys To Add Details Of $130M Talc Settlement In Ch. 11 Docs
- ICC Awards Mitsubishi $33M In Fight With Korean Pharma Co.
- 6 Priorities For Employment-Based Immigration Reform
- Pa. Judge Finds Catheter Makers Owe $1.25M To Inventor
- EU Rule Presents New Medical Device Compliance Hurdles
- Pa. Medical Pot Biz Says Ex-Employee Hacked Network
- Geneticist Tries To Dodge Cloning Suit From Polo Star
- Rite Aid Must Face Trial For Inflated Drug Price Claims
- Fruit Co. Must Destroy Juice In Deal To End FDA Suit
- UK Litigation Roundup: Here's What You Missed In London
- 4 Legal Industry Trends Litigation Financiers Are Watching
- Mallinckrodt Ch. 11 Talks Stalled Amid Fee Row, Judge Told
- DOJ's False Claims Haul Hits Decade Low At $2.2B
- 6th Circ. Won't Stop Ex-FDA Chief's Opioid MDL Testimony
- Biden Floats Stimulus Checks, Credits In $1.9T Of Virus Relief
- Diverse Atty Group Proposed As Lead Counsel In Elmiron MDL
- Medical Pot Producers Want NM Forced To Boost Plant Limit
- Patent Atty Slams Allergan Bid For Quick Appeal In FCA Case
- Lathrop Builds DC Presence With Ad Law Ace
- 3 Takeaways From Senate Insulin Pricing Probe
- Cannabis Firm Wants Pot Co.'s $5M Malpractice Claims Axed
- A Lawyer's Guide To Setting Well-Being Goals In 2021
- 4 Rulings That Will Shape Clickwrap Litigation In 2021
- Suit Dismissed Over Dr. Oz's 'Miracle' Diet Pills
- Lessons From 2020 Life Sciences Securities Class Actions
- Simpson-Steered PE Shop Amasses $10.2B Across 2 Funds
- 3 Firms Seek To Rep Biogen Investors In Securities Fraud Suit
- Whistleblowers Win $5.5M Atty Fees In Boston Scientific Case
- 9th. Circ. Won't Revive Suit Over Target Dietary Supplement
- Stem Cell Clinic Takes On FDA Regulations In 11th Circ.
- Drugmakers Sue HHS To Curtail Discounts To Pharmacies
- PTAB Mulls Analogous Prior Art In Sanofi, Mylan Injector Case
- Cole Schotz Nabs IP Atty From Thompson & Knight
- Keyword Searches To Improve Your Privilege Doc Review
- No Prison For Ex-Acclarent Execs In Off-Label Marketing Case
- United Cannabis' Ch. 11 Dismissed In Blow To Pot Sector
- Assignor Estoppel Case Could Fuel More Patent Attacks
- Justices Let FDA Require Abortion Pill Visits Amid Pandemic
- PBM Lobby Sues To Block Trump's 'Radical' Drug Rebate Rule
- Baxter Dodges Investor Suit Over Forex Accounting, For Now
- Consumers Can't Bring Out-Of-State Claims in Valsartan MDL
- Perrigo Urges US Judge Not To Delay $163.5M Tax Trial
- PTAB Judge Skeptical Allergan's Juvederm Patents Are Valid
- J&J Unhappy With Imerys' Ch. 11 Plan Disclosures
- Feds Want Jury Told Of Ex-Theranos CEO's 'Lavish Lifestyle'
- Pfizer Sues Over Generic For Arthritis Drug Xeljanz
- State AGs' 2020 Actions Offer Hints At 2021 Priorities
- 5 Blank-Check Cos. Raise $1.1B Amid Sizzling IPO Market
- US Trustee Says Mallinckrodt Fee Deals Still Defective
- The Benefits Of More Alternative Dispute Resolution At GAO
- Coronavirus Regulations: A State-By-State Week In Review
- Mass. Neuroscience Co. Minerva Hit With Stock-Drop Suit
- Ex-Acclarent Exec Rips Feds' Jail Request In Off-Label Case
- Food And Beverage Policy Trends To Monitor This Year
- ABA Approves Remote Practice, But Questions Remain
- Jones Day, Wachtell Lead $3.6B Deal For Medical Products Co.
- Impax Investors' Drug Price-Fixing Suit Revived By 9th Circ.
- Ex-FDA Chief Getting Biden Admin. Post, Opioid Atty Says
- Miss. Using 'Zombie Law' To Legalize Medical Pot, City Says
- Illumina Hit With Antitrust Suit Over Alleged Patent Fraud
- Humana Sues Teva Over Alleged Copay Fraud Scheme
- Trump Targets March-In Rights In Proposed Rule Change
- 3rd Circ. Revives Fresenius Generic Drug Suit
- Mylan, Pfizer Fight Remote Testimony In EpiPen Trial
- Name Brand Drug Cos. Ax Labeling Claims In Zantac MDL
- Ten IPOs Could Raise Nearly $5B As 2021 Gets Rolling
- Calif. Pot Agency Consolidation Planned For This Year
- Investors Sue Canadian Nanotech Co. Over COVID-19 Test
- Justices Turn Away 7 More IP Cases, Split Arthrex Arguments
- Greenberg Traurig Brings On Product Liability Atty In Miami
- Research Institute Settles Workers' FLSA Claims For $4.6M
- Calif. Agency Wins Pause Of $1B Destroyed Hemp Crop Suit
- Real Estate Rumors: Woodfield, Kaiser Permanente, Axonic
- GoodRx IPO Timed To Beat Amazon's Rival Launch, Suit Says
- Keys To Creating Standout Law Firm Thought Leadership
- Justices Won't Review Do-Overs Of Whistleblower FCA Cases
- Fed. Circ. Patent Decisions In 2020: An Empirical Review
- Weil, Goodwin Steer Sanofi's Up To $1.45B Bet On Drug Co.
- High Court Won't Nix Nat'l Class Ruling In Ill. Junk-Fax Case
- Becton Buyers Defend Revived Antitrust Suit
- Justices Nix 2nd Circ. Insider Trading Ruling After Bridgegate
- Bell Nunnally Adds IP Partner From Klemchuk
- Top 5 Criminal Justice Reforms Advocates Want Under Biden
- Judges On Race: The Power Of Discretion In Criminal Justice
- Ignore 'Scaremongering' On FCA Circuit Split, Justices Told
- Fed. Circ. Revives Fee Bid In Gardasil Vaccine Injury Case
- Drug. Co. Can't Keep Emails Under Wraps In Valsartan MDL
- DuPont Dodges Ex-Worker's Pregnancy Bias Suit
- Kilpatrick Nabs Ex-MoFo IP Life Sciences Litigator
- DOL Says 'No Checklist' For Ministerial Exception To FLSA
- Pomerantz Asks To Take Lead Of Endo Investors' Suit
- Justices To Review Assignor Estoppel In Patent Cases
- 4 Things Garland Could Do For Marijuana Reform As AG
- Shkreli Can't Pause Suit Pending Prison Release, Judge Says
- Ex-Manager Says 'Stale' Ecolab Docs Aren't Trade Secrets
- Imerys Insurers Say Not Enough Info On $130M Cyprus Deal
- 4 Firms Lead Cancer-Centric Biotechs In IPOs Totaling $459M
- 5 Major Drug And Medical Device Developments In 2020
- Taxation With Representation: Wachtell, Cravath, Skadden
- Convicted Insys Founder Wants Vaccine First, Prison Later
- Cooley, Skadden Rep Cancer Biotech's $1.7B Go-Public Deal
- 5 Attorney Business Development Tips For The New Year
- UK Litigation Roundup: Here's What You Missed In London
- Life Sciences Cos. Increasingly Turn To Arbitration
- Unilever Sued Over Hair Loss, Formaldehyde In Its Shampoos
- Fed. Circ. Judge Suggests Columbia's DNA IP Was Known
- Butler Snow Hires Scott Douglass McConnico Trial Pro
- DOJ Urges Prison Time For Former Acclarent Execs
- HDI Global Shakes Pharma Co.'s Advertising Coverage Row
- Swedish Biotech Oasmia Settles Investor Claims For $2.4M
- NY To Push Back On Efforts To Split Landmark Opioid Trial
- FEMA Finalizes Rule Prioritizing Federal Medical Contracts
- How 2020 Changed Product Liability — And What's Next
- 10 Ways Antitrust Scrutiny Is Heating Up In 2021
- After Lull In Biosimilar IP Litigation, 2021 Could Bring Influx
- Insurers Urge Court To Preserve Cancer Drug Antitrust Suit
- Minimizing Disruption To Clients During Law Firm IT Upgrades
- DOJ Misled Court About Planned Opioid Suit, Walmart Says
- Medical Marijuana Investor Suit Punted Back To Trial Court
- DNA IP Ruling Creates 'Serious Ethical' Issues, Justices Told
- Trump Signs Bill To Organize Drug Patent Listings
- Trump Signs Bill Allowing FDA Seizure Of Counterfeits
- Fed. Circ. Won't Let Bull Semen Co. Appeal Moot PTAB Loss
- Fed. Circ. Won't Revive Axed Horizon Pain Drug Patents
- White House Slams 'Opportunistic' COVID-19 Scammers
- US, EU Call Out India During WTO's Trade Review
- Moderna COVID-19 Vaccine Gets OK'd In EU
- W.Va. Opioid Distributor Bellwether Trial Set For May
- More Than 20 Firms Guided The Top Real Estate Deals Of 2020
- 4th Circ. Undoes $1.25M Verdict In Pradaxa Suit
- Gov't Pandemic Response Will Boost Life Sciences In 2021
- FCA Whistleblowers Are More Important Than Ever Before
- Allergan Says Federal Law Preempts Breast Implant Claims
- 10 Patent Prosecution, Litigation Practice Trends From 2020
- Real Estate Rumors: Ross, Magellan, East West Development
- 5th Circ. Told To Undo Sanofi's Win In Chemo Hair Loss Row
- Pot Legalization Still Faces Hurdles After Senate Flip
- Feds Want In On Allergan Collusion Suit Amid Criminal Probe
- Hatch-Waxman Venue Issue Still Live After Fed. Circ. Ruling
- Tips For Drafting Effective Amicus Briefs
- 5 Firms Drive $6.5B Sale Of Walgreens' Health Care Division
- Mylan Urges Fed. Circ. To Keep Hatch-Waxman Venue Limits
- 8th Circ. Affirms Injunction Blocking 2 Ark. Abortion Laws
- Ga. Board Pushes 11th Circ. For Immunity From SmileDirect
- NY Legislators Refile Bill To Legalize Cannabis
- Biomet Strikes Back Against $3.5M Hip Implant Verdict
- Investors Say NJ Firm Snuck Off With $2.6M In Pot Profits
- Split 11th Circ. Upholds Magellan Health Noncompete
- Merck, Glenmark Fight Zetia Class Cert. At 4th Circ.
- Coronavirus Regulations: A State-By-State Week In Review
- 5 Trends That Will Influence E-Discovery In 2021
- Health Care Co. Appeals Contract Terminations To 6th Circ.
- Virus Prompts Delay Of Del. Trial Over Testosterone Drug
- John Wiley Buys Open Access Publisher For $298M
- DC Judge Calls Teva's Bid To Reclassify Drug Anticompetitive
- Allergan Seeks Quick Appeal After Failing To Nix FCA Suit
- Gilead 'Rewriting' History To Save $2.5B IP Win, Justices Told
- Inventors Urge Justices To Restore Patent Balance In Arthrex
- Special Masters Tapped In Valsartan Contamination MDL
- DOJ Attys Dish On Indivior Opioid Case As Sentencing Wraps
- PhRMA Denied Early Win In Drug Pricing Law Case
- B. Braun Medical Ex-Workers Fight To Save 401(k) Fee Dispute
- Skadden-Led Dental Products Co. Buys Aligner Maker For $1B
- DOJ Backs AbbVie At 7th Circ. In 'Patent Thicket' Case
- Overlooked Patent Cases: Willful Infringement Developments
- Pair Of Cancer-Focused Biotechs Launch IPOs Totaling $300M
- Prep For Increased Pay Equity Enforcement In Gov't Contracts
- Zantac Generics MDL Labeling Claims Axed As Preempted
- Calif. Federal Forum Clause Rulings Are Good News For Cos.
- How Relationship Partners Can Draft Winning RFP Responses
- Securities Litigation Trends That Will Matter Most In 2021
- Antitrust Conduct Cases To Watch In 2021
- Law Firm Merger Predictions For 2021
- Epic Litigation Landscape Awaits Health, Life Sci Attys In 2021
- Patent Policy To Watch In 2021
- 2020 ERISA Litigation Trends Hint At What's Ahead This Year
- 4 Key Areas As Biden Sets New Health Policy Path In 2021
- Patent Cases To Watch In 2021
- Product Liability Cases To Watch In 2021
- Cannabis Policy Items To Watch In 2021
- 2021 Trials To Watch As Litigants Return To Court — Hopefully
- ERISA Arbitration, New Legal Theories To Be Tested In 2021
- The Biggest UK IP Cases To Watch In 2021
- Lessons For 2021 From Fed. Circ. Post-Grant Review Cases
- California Cases To Watch In 2021
- California Legislation And Regulation To Watch In 2021
- Top Gov't Contracts Cases To Watch In 2021
- Patent Litigation Trends To Watch In 2021